Roche Q3 2026 Results: Sales Rise 7%, Xolair Misses
The Roche Q3 2026 results: sales up 7% to CHF 16.13 billion, Ocrevus up 9%, and Xolair below forecasts as a lower-priced rival arrives.
The Roche Q3 2026 results: sales up 7% to CHF 16.13 billion, Ocrevus up 9%, and Xolair below forecasts as a lower-priced rival arrives.